Beyond Ozempic: The New Generation of Weight-Loss Peptides

Semaglutide, tirzepatide, retatrutide and eloralintide aren’t just stronger versions of the same drug. They’re four very different ideas about how to talk to your metabolism, and the results are rewriting what we thought was possible.

A few years ago, losing 15% of your body weight with a medication was considered extraordinary.

Now clinical trials are reporting average losses approaching 30%, territory that used to belong almost exclusively to bariatric surgery.

That’s a stunning shift. But the most interesting part isn’t the size of the number on the scale. It’s how differently these new molecules are designed to work.

In under a decade, metabolic medicine has moved from activating one gut-hormone receptor to two, then three. Now researchers are exploring another hormone, amylin, which could open an entirely new avenue.

If you’ve heard the names Ozempic, Mounjaro, Zepbound or the increasingly talked about retatrutide, you’ve already caught pieces of this story.

Here’s how it all fits together.

First, GLP-1 Isn’t Really a “Weight Loss Hormone”

At least, not only that.

GLP-1, short for glucagon-like peptide-1, is a hormone your intestines release after you eat. It’s one of your body’s internal messengers: it helps tell your pancreas when to release insulin, slows how quickly food leaves your stomach, and communicates with areas of your brain that regulate hunger and fullness.

In other words, it’s part of how your body knows you’ve eaten.

The catch is that natural GLP-1 is a sprinter, not a marathoner. It’s broken down within minutes. Medications like semaglutide are engineered to activate the same receptor for much longer, allowing those signals to remain active.

For many people, that changes the entire experience of eating.

Meals become more satisfying. Hunger gets quieter. And the constant mental back-and-forth about whether to have that thing sitting in the pantry can finally go silent.

That last effect has earned its own popular name: food noise.

It isn’t a formal medical diagnosis, but it’s a remarkably relatable description. Many people don’t realize how loud those thoughts were until they become quieter.

And that brings us to the medication that changed the conversation.

Semaglutide: The Drug That Changed the Conversation

Semaglutide, better known by its brand names Ozempic and Wegovy, is a GLP-1 receptor agonist. It activates one primary hormone receptor.

That sounds relatively simple compared with what came later.

The results were anything but.

In the landmark STEP 1 clinical trial, 1,961 adults with obesity or overweight and a weight-related condition, without diabetes, were studied over 68 weeks.

Participants receiving once-weekly injectable semaglutide 2.4 mg lost an average of 14.9% of their starting body weight, compared with 2.4% in the placebo group.

For someone starting at 200 pounds, that’s nearly 30 pounds.

And this wasn’t just a handful of exceptional responders. It was the average across the treatment group.

The results also extended beyond the scale. Researchers observed improvements in several cardiometabolic risk factors, including waist circumference and blood pressure.

But perhaps the most important shift was in how we understood weight management itself.

For decades, the conversation revolved around willpower, calorie counting, and exercise. Those things still matter, of course. But semaglutide demonstrated just how powerfully biological signaling can influence appetite and body weight.

For people who had spent years fighting persistent hunger, that was a meaningful development.

And it raised an even more interesting question.

If activating one hormone receptor could produce results like these, what might happen if researchers activated two?

Tirzepatide: Why Two Hormones Can Work Better Than One

If semaglutide changed the conversation, tirzepatide took it somewhere even more interesting.

Sold under the brand names Mounjaro and Zepbound, tirzepatide activates two hormone receptors instead of one: GLP-1 and GIP.

We’ve already met GLP-1. But GIP, short for glucose-dependent insulinotropic polypeptide, has a rather interesting history.

Like GLP-1, it’s released by the intestines after eating and helps regulate insulin secretion. But GIP also interacts with signaling pathways in the brain and fat tissue, and its role in weight regulation has been surprisingly complicated.

For years, researchers weren’t entirely sure whether stimulating the GIP receptor would help people lose weight or potentially work against that goal.

After all, GIP participates in how the body handles and stores nutrients. Activating it didn’t initially sound like the most obvious strategy for reducing body fat.

But biology rarely follows such tidy assumptions.

When researchers combined GIP and GLP-1 receptor activation in a single molecule, the results were remarkable.

And eventually, we got something even more valuable than separate clinical trials.

A direct comparison.

The Head-to-Head Trial That Settled an Important Question

In the SURMOUNT-5 trial, researchers studied 751 adults with obesity, without diabetes, over 72 weeks.

Participants received either once-weekly injectable tirzepatide or injectable semaglutide, with doses increased according to the study protocol.

The average weight-loss results were striking:

• Tirzepatide: 20.2%
• Semaglutide: 13.7%

For someone beginning at 200 pounds, that’s approximately 40 pounds versus 27 pounds.

A difference of roughly 13 pounds.

And unlike comparisons between unrelated studies, these results came from participants evaluated within the same clinical trial.

That matters enormously.

Different studies can produce different outcomes because of participant characteristics, treatment duration, doses, and other factors. A randomized head-to-head trial eliminates many of those uncertainties.

In this population, tirzepatide produced significantly greater average weight loss than semaglutide.

But here’s the part I find particularly fascinating.

Why Does Adding GIP Make Such a Difference?

You might assume that activating two receptors simply means doubling the appetite-suppressing effect.

It’s not quite that straightforward.

GLP-1 and GIP have overlapping roles in glucose regulation, but they also have distinct biological effects.

Scientists are investigating how GIP signaling influences appetite-regulating brain circuits, insulin sensitivity, and the body’s response to nutrients.

There’s also evidence that combining the two pathways may produce effects that aren’t fully explained by either receptor acting alone.

Researchers are still working out precisely how much of tirzepatide’s weight-loss advantage comes from GIP signaling, how much comes from the combined receptor activity, and how the molecule’s particular pharmacology contributes.

That’s an important distinction: we know the combination works exceptionally well in clinical trials, even though the complete biological explanation is still evolving.

And there’s another reason these findings matter.

Tirzepatide didn’t simply demonstrate that scientists could make a stronger version of semaglutide.

It showed that combining different hormonal signals could meaningfully change treatment outcomes.

That opened the door to an entirely new generation of metabolic research.

Because once researchers saw what two receptors could accomplish together, the next question was almost irresistible.

What happens when you add a third?

Retatrutide: The Triple-Agonist Approach

This is where metabolic peptide research gets genuinely thrilling.

Semaglutide activates one receptor. Tirzepatide activates two.

Retatrutide activates three: GLP-1, GIP, and glucagon.

Yes, glucagon.

If you remember anything from high school biology, it’s probably that glucagon raises blood sugar. So why would researchers deliberately activate a glucagon receptor in a medication designed to improve metabolic health?

Because glucagon turns out to be much more interesting than that.

The Surprising Science Behind Glucagon

Glucagon is produced by the pancreas, and one of its primary jobs is helping maintain blood glucose levels when we haven’t eaten.

But that’s only part of its story.

Glucagon also influences how the liver processes nutrients, how the body mobilizes stored energy, and potentially how much energy we expend.

And that’s what makes retatrutide so intriguing.

While GLP-1 and GIP help regulate appetite and glucose metabolism, adding glucagon-receptor activity introduces another dimension to the treatment.

Rather than focusing exclusively on how much someone eats, researchers are also exploring how the body uses energy.

Think of it as approaching weight management from two directions: the energy coming in and the energy being used.

There’s an important nuance here. Although glucagon signaling can increase energy expenditure under certain experimental conditions, scientists are still determining how much that contributes to retatrutide’s remarkable weight-loss results in humans.

We shouldn’t assume the third receptor is responsible for a particular percentage of weight loss.

But the strategy itself is fascinating.

And the clinical results have given researchers plenty of reasons to keep investigating.

The Numbers That Made Headlines

In a 2023 Phase 2 trial involving 338 adults with obesity or overweight and a weight-related condition, the highest studied retatrutide dose produced an average 24.2% reduction in body weight after 48 weeks, compared with 2.1% in the placebo group.

Nearly one-quarter of starting body weight in less than a year.

For perspective, someone beginning at 250 pounds would lose approximately 60 pounds at that average percentage.

Then came the larger Phase 3 TRIUMPH-1 trial.

At 80 weeks, participants assigned to the 12 mg retatrutide group achieved approximately 25.0% average weight loss in the primary treatment-regimen analysis.

An additional efficacy analysis, which estimated outcomes under continued treatment, reported 28.3% average weight loss.

That distinction matters because the two figures answer slightly different statistical questions. The larger number isn’t necessarily what every person starting treatment should expect.

Either way, these results represent a major advance in metabolic medicine.

And the research isn’t limited to weight alone. Investigators are examining retatrutide’s effects on cardiometabolic measures, liver fat, and obesity-related health conditions.

What We’re Still Learning

As impressive as those numbers are, there’s one comparison we need to be careful about.

Retatrutide’s results cannot simply be placed next to tirzepatide’s 20.2% figure and treated as proof that one medication is superior.

Those findings don’t erase the promise of the research. They help define the questions that larger and longer studies need to answer.

And as of October 2026, retatrutide remains an investigational compound rather than an FDA-approved weight-management medication.

But here’s what I find most exciting about its development.

Retatrutide isn’t simply an attempt to make people feel fuller. It’s an effort to influence several interconnected metabolic pathways with one carefully engineered molecule.

That’s a meaningful shift in how scientists are approaching obesity and metabolic health.

And just when it seemed that adding more receptors might be the defining strategy of the next generation, another hormone began attracting serious attention.

One that doesn’t depend on GLP-1, GIP, or glucagon at all.

Its name is amylin.

Eloralintide: What If the Next Breakthrough Isn’t Another GLP-1?

Just when it seemed that the future of weight-loss medicine was all about adding more receptors to GLP-1, researchers started exploring a different hormone altogether.

Meet eloralintide.

And here’s why it’s particularly interesting: eloralintide doesn’t activate GLP-1, GIP, or glucagon receptors.

Instead, it’s designed to activate receptors for amylin, a hormone your pancreas naturally releases alongside insulin when you eat.

Amylin helps regulate how quickly food leaves your stomach, how much you eat during a meal, and when your brain decides you’ve had enough.

That might sound familiar. After all, GLP-1 influences some of those same processes.

But the biology is different.

Same Destination, Different Route

Think of GLP-1 and amylin as two separate conversations happening inside your body.

GLP-1 communicates with several systems involved in appetite, insulin secretion, and glucose regulation.

Amylin works through its own network of receptors, including pathways in the brainstem that help control meal size and fullness.

One particularly interesting region is called the area postrema, which participates in sensing circulating signals and communicating with other brain regions involved in appetite.

These pathways overlap in what they accomplish, but they aren’t identical.

And that distinction opens up an intriguing possibility.

What if researchers could influence appetite through different biological systems, rather than simply increasing the activity of one?

That’s part of the thinking behind eloralintide.

The Clinical Results Are Getting Interesting

In a Phase 2 clinical trial involving 263 adults with obesity or overweight and a related health condition, researchers evaluated different eloralintide regimens over 48 weeks.

Average weight reductions ranged from approximately 9% to 20%, depending on the treatment regimen, compared with approximately 0.4% in the placebo group.

For a compound targeting the amylin pathway rather than GLP-1, those findings are noteworthy.

And they suggest that significant weight reduction may be achievable through more than one hormonal strategy.

Of course, these are Phase 2 findings. Larger studies are needed to establish how eloralintide performs across different populations, how well its effects are maintained, and what its longer-term safety profile looks like.

But the underlying idea is compelling.

We may be moving toward an era in which metabolic treatments are designed around several complementary hormone systems.

Which brings us to an even more interesting experiment.

EloraTZP: What Happens When Amylin Meets Tirzepatide?

Remember that tirzepatide already activates two receptors: GLP-1 and GIP.

Now imagine combining those effects with a selective amylin receptor agonist.

That’s the idea behind EloraTZP, an investigational combination of eloralintide and tirzepatide.

Together, the treatments engage three hormone pathways:

• GLP-1
• GIP
• Amylin

But unlike retatrutide, which combines GLP-1, GIP, and glucagon activity within a single molecule, EloraTZP brings together two distinct compounds.

It’s a different approach to reaching multiple biological targets.

The Early Results

In September 2026, Eli Lilly reported results from a 48-week Phase 2b trial involving 367 adults with obesity or overweight and type 2 diabetes.

The highest reported average weight reduction with the combination was 23.3%, compared with 14.8% for tirzepatide 15 mg alone.

That’s a substantial difference.

And importantly, this study included a direct tirzepatide comparison, making the results more informative than simply comparing percentages from unrelated trials.

The study also reported greater improvements in blood glucose measures with the combination.

There’s another interesting detail: people with type 2 diabetes often experience somewhat smaller average weight reductions with incretin-based treatments than comparable trial populations without diabetes.

That makes the findings particularly noteworthy, although we’ll need larger studies to understand how broadly they apply.

Why This Matters Beyond the Numbers

The most exciting part isn’t necessarily that researchers achieved another impressive weight-loss percentage.

It’s what the combination tells us about the direction of metabolic medicine.

Retatrutide explores what happens when glucagon signaling joins GLP-1 and GIP.

EloraTZP explores what happens when amylin joins GLP-1 and GIP.

Both approaches engage three hormonal pathways, but they aren’t doing the same thing.

And that raises questions worth investigating.

Could different combinations eventually be better suited to different metabolic needs? Could one approach offer advantages for particular patients, or produce a different balance of appetite regulation, glucose control, and tolerability?

We don’t have those answers yet.

The combination also has important tolerability questions to resolve. In the Phase 2b study, treatment discontinuations were more frequent in some combination groups, underscoring the importance of optimizing how the drugs are administered and increased over time.

But that’s part of what clinical development is designed to investigate.

The next breakthrough may not be one molecule that does everything. It may be learning which hormonal pathways work best together, and for whom.

And suddenly, the future of metabolic peptides looks considerably more interesting than a competition over which medication produces the biggest number on the scale.

The Comparison: Five Approaches, Five Different Strategies

It’s tempting to look at the weight-loss percentages and declare a winner.

But that would miss the most interesting part of the story.

These compounds aren’t simply different strengths of the same medication. They’re designed to influence different hormonal pathways, sometimes in entirely different ways.

Here’s how they compare.

Compound	Hormonal targets	Selected clinical result
Semaglutide	GLP-1	14.9% average weight loss at 68 weeks
Tirzepatide	GLP-1 + GIP	20.2% at 72 weeks
Retatrutide	GLP-1 + GIP + glucagon	25.0% at 80 weeks in the primary analysis; 28.3% in an additional efficacy analysis
Eloralintide	Amylin	Up to approximately 20% at 48 weeks
EloraTZP	GLP-1 + GIP + amylin	Up to 23.3% at 48 weeks in participants with type 2 diabetes

These results come from different clinical trials, with different populations, treatment durations, and statistical methods. They aren’t a direct ranking of effectiveness. Tirzepatide’s figure comes from its head-to-head comparison with semaglutide, while EloraTZP’s study included a direct tirzepatide comparison.

As of October 2026, injectable semaglutide and tirzepatide are approved weight-management treatments in the United States. Retatrutide, eloralintide, and EloraTZP remain investigational.

What stands out isn’t simply that the percentages are getting larger.

It’s that researchers are learning how to influence metabolism through increasingly sophisticated combinations of biological signals.

Semaglutide demonstrated what sustained GLP-1 signaling could accomplish.

Tirzepatide showed that adding GIP could meaningfully improve average weight-loss outcomes.

Retatrutide introduced glucagon signaling into the equation, opening questions about energy expenditure and fuel metabolism.

And eloralintide demonstrated that the amylin pathway deserves serious attention in its own right.

The real story isn’t five medications competing for first place. It’s five approaches expanding what metabolic medicine may eventually be able to accomplish.

The Muscle Question: What Exactly Are We Losing?

Here’s something that doesn’t get nearly enough attention in conversations about weight-loss medications.

When someone loses 40, 50, or even 70 pounds, what exactly makes up those pounds?

Because the scale can’t distinguish between fat, muscle, water, and other tissues.

And after 40, that distinction becomes increasingly important.

We naturally become more vulnerable to losing muscle as we age, particularly when physical activity declines or hormonal changes affect body composition.

Now introduce a medication that can dramatically reduce appetite.

For someone who has struggled with persistent hunger, that can be a tremendous relief.

But there’s an important difference between eating less and eating well.

What the Body-Composition Research Shows

In an exploratory body-composition analysis of the STEP 1 semaglutide trial, researchers used DXA scans to examine changes in fat and lean tissue.

Participants experienced substantial reductions in total body fat and visceral fat, the deeper abdominal fat associated with increased metabolic risk.

Their total lean body mass also declined.

That finding sometimes gets presented as evidence that GLP-1 medications cause muscle wasting.

But that’s an oversimplification.

Lean body mass isn’t the same thing as skeletal muscle. It includes water, organs, and other nonfat tissues. And when people lose significant amounts of weight, some reduction in lean mass is common, whether the weight loss comes from medication, dietary changes, or bariatric surgery.

There’s another important detail: although absolute lean mass declined in the STEP 1 analysis, lean mass increased as a proportion of total body weight.

In other words, participants generally became leaner, with a larger share of their remaining body weight consisting of nonfat tissue.

That’s an important distinction.

And there’s an encouraging side to these findings, too.

Reducing excess body fat, particularly visceral fat, can substantially improve metabolic health. The opportunity now is to combine those benefits with strategies that help preserve strength and physical function as weight comes down.

Why This Matters More After 50

Muscle isn’t just something we need for looking toned.

It’s essential for glucose regulation, mobility, balance, and maintaining independence as we get older.

And muscle tissue plays an important role in how the body handles glucose after a meal.

That means preserving muscle during substantial weight loss isn’t simply a cosmetic concern.

It’s part of protecting long-term metabolic health.

For adults in their 50s and 60s, several practical strategies become especially relevant:

• Resistance training: Challenging muscles regularly gives the body a reason to maintain them.
• Adequate protein: When appetite drops significantly, protein intake can fall without someone realizing it.
• Nutritional quality: Eating smaller amounts makes the nutrient content of those meals more important.
• Monitoring strength: Body weight alone doesn’t tell us whether someone is maintaining physical function.

And here’s a question I’d love to see more research address.

As increasingly powerful metabolic peptides make substantial weight reduction possible, can treatment strategies become more sophisticated about protecting muscle at the same time?

Researchers are already exploring body composition and muscle preservation as important areas of obesity-treatment research.

That may ultimately become just as interesting as the weight-loss percentages themselves.

Because losing excess fat is valuable. Losing excess fat while maintaining the strength, mobility, and energy to enjoy the benefits is even better.

Side Effects: Why the Differences Matter

With weight-loss results approaching 25% or even 30% in some clinical trials, it’s understandable that much of the attention goes to effectiveness.

But another part of the research is equally interesting: how well people tolerate these medications, and whether different hormone pathways produce different experiences.

Most of the compounds we’ve discussed share some familiar gastrointestinal side effects, particularly nausea, vomiting, diarrhea, and constipation.

That’s not surprising. Several of these hormonal pathways influence appetite, digestive activity, and how quickly food leaves the stomach.

But the medications aren’t identical, and neither are their side-effect profiles.

What Changes When You Add More Receptors?

Semaglutide and tirzepatide have the advantage of extensive clinical research and real-world prescribing experience. Their benefits, limitations, and important safety warnings are relatively well characterized.

Retatrutide introduces glucagon-receptor activity, which raises additional questions about heart rate, cardiovascular physiology, and how the different pathways interact over time.

In clinical trials, researchers have observed increases in heart rate alongside gastrointestinal side effects. Understanding the long-term significance of those findings remains part of the ongoing research.

Eloralintide presents a different picture.

Because it activates the amylin pathway, researchers are particularly interested in how it affects fullness, nausea, and gastric emptying.

And when eloralintide is combined with tirzepatide, there’s another challenge: finding a treatment schedule that allows people to benefit from multiple hormonal pathways without making the medication unnecessarily difficult to tolerate.

That might sound like a relatively minor detail, but it isn’t.

A medication’s effectiveness depends partly on whether people can comfortably remain on treatment long enough to experience its benefits.

Why Starting Slowly Matters

One interesting feature of many metabolic-peptide clinical trials is that participants don’t begin at the highest studied dose.

Instead, researchers use carefully designed dose-escalation schedules, gradually increasing exposure while monitoring tolerability.

This approach can help reduce gastrointestinal side effects, although it doesn’t eliminate them.

It also illustrates why a clinical trial result is more than a molecule and a headline percentage.

The formulation, administration schedule, patient selection, and medical monitoring are all part of the treatment being studied.

For investigational compounds, those details are still being refined.

And that’s one reason the results of controlled clinical trials shouldn’t be assumed to apply to products or dosing approaches outside those trials.

What Happens When You Stop Taking a GLP-1 Medication?

Here’s a question that deserves considerably more attention.

If a medication helps regulate hunger and fullness through hormonal signaling, what happens when that medication is discontinued?

Do those changes become permanent?

Or does the body’s previous appetite regulation begin to return?

Researchers have already started answering that question.

What the STEP 1 Extension Revealed

In an extension of the original STEP 1 semaglutide trial, researchers followed participants after treatment and the structured lifestyle intervention ended.

Over the following year, participants who had received semaglutide regained approximately two-thirds of the weight they had previously lost, on average.

That finding understandably attracted attention.

But I think there’s a more useful way to interpret it.

The medication had been influencing biological systems involved in appetite and weight regulation. Once treatment stopped, those systems were no longer receiving the same pharmacological signals.

And for many participants, weight began returning.

That doesn’t mean the medication failed.

It suggests that obesity, particularly when longstanding, often involves persistent biological mechanisms that don’t simply disappear after weight loss.

We’ve seen similar questions arise with other weight-management treatments.

And it’s changing the way researchers and clinicians think about long-term care.

From Short-Term Weight Loss to Long-Term Metabolic Management

For years, weight loss was often presented as a temporary project.

Lose the weight. Reach the goal. Return to normal life.

But metabolic biology doesn’t necessarily cooperate with that model.

Appetite, energy expenditure, hormonal signaling, and the body’s responses to weight reduction can continue influencing weight long after someone reaches a target.

That’s why there’s growing interest in understanding obesity treatment as ongoing metabolic management rather than simply a short course of medication.

It also raises important questions about newer compounds.

Will retatrutide produce similar patterns of weight regain after discontinuation?

Could amylin-based treatments influence long-term appetite regulation differently?

Might future combinations or maintenance strategies help people sustain results with different treatment approaches?

We don’t have definitive answers yet.

But these are precisely the kinds of questions that make the next generation of metabolic research so interesting.

The future isn’t just about how much weight someone can lose. It’s about how effectively those improvements can be maintained, and what they mean for health years later.

What’s Coming Next? The Future of Metabolic Peptides

If the last decade taught us anything, it’s that metabolic medicine is evolving much faster than most people expected.

We’ve moved from activating a single hormone receptor to developing compounds that influence several pathways simultaneously. And the next generation may be even more sophisticated.

Researchers are investigating combinations that target appetite and satiety through different mechanisms, compounds that influence energy expenditure and liver metabolism, and approaches that may eventually help preserve more muscle during substantial weight loss.

The particularly interesting development is that these strategies aren’t necessarily competing with one another.

Retatrutide explores the addition of glucagon signaling to GLP-1 and GIP.

Eloralintide introduces the amylin pathway.

And combinations such as EloraTZP investigate what happens when those different hormonal systems work together.

Each represents a different way of approaching the same larger challenge: improving metabolic health by understanding and influencing the body’s own biological signaling.

What About Oral GLP-1 Medications?

Oral GLP-1 medications are entering the picture, too, offering another approach for people who prefer tablets to injections.

But formulation matters, and not every oral treatment delivers the same clinical results as its injectable counterparts. Absorption, dosing, and the specific molecule all influence effectiveness.

For now, injectable therapies remain central to some of the most compelling weight-loss research, particularly as scientists explore dual- and triple-receptor agonists.

And while convenience will always matter, the more interesting question is what each treatment can actually accomplish.

The Next Question Isn’t Simply Who Loses the Most Weight

It’s tempting to imagine that the future belongs to whichever compound produces the largest percentage on a clinical-trial chart.

But I suspect the more meaningful advances will be considerably more nuanced.

Could one hormonal combination be particularly effective for people with insulin resistance?

Might another offer advantages for people with significant liver fat or other metabolic complications?

Could future treatments help protect muscle and physical function while reducing excess body fat?

And might researchers eventually identify which biological pathways are most relevant for different individuals, rather than approaching everyone with the same treatment strategy?

These are still research questions, not established treatment distinctions.

But they’re exciting ones.

Because the real opportunity isn’t simply to develop increasingly powerful weight-loss medications.

It’s to understand metabolism well enough to make treatment more precise, more sustainable, and ultimately more useful for the people receiving it.

September Wellness provides educational information about published and emerging scientific research. This article is not medical advice or a recommendation to use investigational compounds. Clinical-trial results reflect specific study populations, formulations, and treatment protocols. Investigational peptides have not necessarily established their long-term safety or effectiveness and should not be assumed equivalent to approved medications.

Sources & Further Reading

1. Wilding, J. P. H., et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021.

The landmark STEP 1 trial involving 1,961 adults. Participants receiving injectable semaglutide 2.4 mg experienced an average 14.9% reduction in body weight over 68 weeks, compared with 2.4% for placebo.

2. Aronne, L. J., et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine, 2025.

The SURMOUNT-5 randomized head-to-head trial involving 751 adults without diabetes. It provides direct clinical evidence comparing the weight-loss effectiveness of injectable tirzepatide and semaglutide.

3. Jastreboff, A. M., et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023.

The Phase 2 study investigating retatrutide’s combined GLP-1, GIP, and glucagon receptor activity. The highest studied dose produced an average 24.2% weight reduction at 48 weeks.

4. TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine, 2026.

The larger Phase 3 study examining retatrutide over 80 weeks. Particularly relevant to understanding the distinction between treatment-regimen and efficacy analyses, as well as the compound’s tolerability and cardiometabolic effects.

5. Eloralintide Phase 2 Investigators. Eloralintide, a Selective Amylin Receptor Agonist for the Treatment of Obesity: A 48-Week Phase 2, Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial. The Lancet, 2025.

A randomized trial involving 263 adults examining an amylin-based approach to weight management. The findings help explain why researchers are investigating appetite-regulating pathways beyond GLP-1.

6. Eli Lilly and Company. EloraTZP Combination of Eloralintide and Tirzepatide: Phase 2b Clinical Trial Results. Company clinical-trial announcement, September 2026.

Reports early findings from combining amylin-receptor activation with GLP-1 and GIP signaling. This is company-reported evidence and should be distinguished from a peer-reviewed clinical publication.

7. Wilding, J. P. H., et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension. Diabetes, Obesity and Metabolism, 2022.

Examines what happened after semaglutide treatment and structured lifestyle intervention ended. Participants regained approximately two-thirds of their previous weight loss over the following year, on average.

8. Wilding, J. P. H., et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society, 2021.

An exploratory analysis using DXA scans to examine changes in body fat, visceral fat, and lean body mass during semaglutide treatment. Useful for understanding why weight loss and muscle preservation deserve separate consideration.